RxDoctor Payments DataLook up a doctor →

Tanios Bekaii-Saab, MD

Hematology & Oncology · Scottsdale, AZNPI 1598770331

Payments from drug & device makers

$31,393,729in general payments, 2019–2025

Across 1,121 payments — averaging $28,005 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11.4M
  • Seagen Inc.$8.1M
  • Array Biopharma Inc$2.3M
  • Amgen$1.6M
  • E.r. Squibb & Sons, L.L.C.$1.3M
  • Ipsen Biopharmaceuticals, Inc$1.3M
  • plus $5.4M from 54 others
$13,641in research payments, 2019–2025

Across 11 payments — averaging $1240.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$12K
  • Bristol Myers Squibb$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer146$11,363,589
Seagen Inc.222$8,099,324
Array Biopharma Inc15$2,313,858
Amgen4$1,624,939
E.r. Squibb & Sons, L.L.C.20$1,313,556
Ipsen Biopharmaceuticals, Inc21$1,281,176
Mirati Therapeutics, Inc.30$981,218
Genentech, Inc.47$694,209
Incyte Corporation197$594,781
Bayer99$528,467
Servier Bioinnovation6$460,562
Merck41$417,346
AstraZeneca30$354,361
Ipsen Bioscience Inc.21$216,438
Karyopharm Therapeutics Inc.2$209,490
Boehringer Ingelheim11$166,638
Astrazeneca UK Limited5$122,234
Boehringer Ingelheim International GmbH21$89,483
EMD Serono, Inc.6$79,700
Biontech SE22$68,223
Novartis4$68,122
Taiho Oncology, Inc.1$50,000
Eli Lilly4$47,560
Exelixis Inc.19$35,303
Takeda Pharmaceuticals U.S.A., Inc.13$30,988
AbbVie20$27,118
Clovis Oncology, Inc.1$17,723
Institut DE Recherches Internationales Servier3$14,952
Genentech USA, Inc.11$12,675
Daiichi Sankyo Inc.3$12,500
Deciphera Pharmaceuticals Inc.2$8,950
Swedish Orphan Biovitrum AB1$7,800
GSK4$7,225
Servier Pharmaceuticals LLC2$7,040
Sanofi2$6,705
Regeneron6$6,466
Eisai Inc.3$6,268
Janssen Global Services, LLC3$4,960
Boehringer Ingelheim Pharma GmbH & Co.kg11$4,683
Partner Therapeutics, Inc.12$4,186
Whitehall International Inc1$3,244
Genmab U.S., Inc.1$3,200
Beigene, Ltd.1$2,775
Beigene USA, Inc.1$2,625
Boston Scientific3$2,593
Stemline Therapeutics Inc.1$2,560
Jazz Pharmaceuticals Inc.2$2,361
Coherus Oncology, Inc.1$2,013
Illumina, Inc.1$1,908
Foundation Medicine, Inc.1$1,750
Sumitomo Pharma Co., Ltd.1$1,400
ADIR1$1,100
Sanofi-aventis U.S. LLC1$1,082
Celularity Inc.1$1,000
Blueprint Medicines Corporation1$924
Institut DE Recherches Servier3$701
Lilly USA, LLC1$700
Tempus AI, Inc3$293
Caris MPI, Inc.1$248
AVEO Pharmaceuticals, Inc.1$161

How this compares

$31,393,729 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024
$86,876
Medicare patients
115
Services billed
1,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →